Pfizer Quarterly Report Form 10-Q Q3 2025

These sources provide an overview of Pfizer's third-quarter 2025 financial performance and corporate activities, primarily through excerpts from an earnings call, a press release, and a quarterly report on Form 10-Q. Key information includes the raising and narrowing of 2025 Adjusted diluted Earnings Per Share (EPS) guidance to a range of $3.00 to $3.15, while reaffirming total revenue guidance of $61.0 to $64.0 billion. The documents discuss major strategic initiatives, such as the proposed acquisition of Metsera for approximately $4.9 billion to compete in the obesity market, as well as a landmark agreement with the U.S. government to reduce drug costs and invest in domestic manufacturing. Financial details highlight a 6% decline in total revenues for the third quarter, largely due to reduced demand for COVID-19 products like Paxlovid and Comirnaty, which was partially offset by strong performance from products like Eliquis and the Vyndaqel family. The filings also address ongoing patent litigation and the anticipated unfavorable impact of the Inflation Reduction Act (IRA) on net revenue.